Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Is self-efficacy for smoking abstinence a cause of, or a reflection on, smoking behavior change?

Perkins KA, Parzynski C, Mercincavage M, Conklin CA, Fonte CA.

Exp Clin Psychopharmacol. 2012 Feb;20(1):56-62. doi: 10.1037/a0025482. Epub 2011 Sep 12.

2.

Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence.

Perkins KA, Mercincavage M, Fonte CA, Lerman C.

Psychopharmacology (Berl). 2010 May;210(1):45-51. doi: 10.1007/s00213-010-1816-9. Epub 2010 Mar 20.

3.

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ.

Pharmacoeconomics. 2011 Jun;29(6):497-510. doi: 10.2165/11589230-000000000-00000.

PMID:
21452908
4.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
5.

Predictors of quit attempts and abstinence among smokers not currently interested in quitting.

Jardin BF, Carpenter MJ.

Nicotine Tob Res. 2012 Oct;14(10):1197-204. Epub 2012 Mar 1.

6.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
7.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
8.

Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.

Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, Smith C, Abdool-Gaffar MS, Emanuel S, Esterhuizen TM, Irusen EM.

JAMA. 2014 Jul;312(2):155-61. doi: 10.1001/jama.2014.7195.

PMID:
25005652
9.

Relapse dynamics during smoking cessation: recurrent abstinence violation effects and lapse-relapse progression.

Kirchner TR, Shiffman S, Wileyto EP.

J Abnorm Psychol. 2012 Feb;121(1):187-97. doi: 10.1037/a0024451. Epub 2011 Jul 25.

10.
11.

A cross-lagged path analysis of five intrapersonal determinants of smoking cessation.

Castro Y, Cano MÁ, Businelle MS, Correa-Fernández V, Heppner WL, Mazas CA, Wetter DW.

Drug Alcohol Depend. 2014 Apr 1;137:98-105. doi: 10.1016/j.drugalcdep.2014.01.013. Epub 2014 Jan 31.

12.

Cross-validation of a new procedure for early screening of smoking cessation medications in humans.

Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KN, Jain A.

Clin Pharmacol Ther. 2010 Jul;88(1):109-14. doi: 10.1038/clpt.2010.65. Epub 2010 May 19.

PMID:
20485335
13.

Interventions for preventing weight gain after smoking cessation.

Farley AC, Hajek P, Lycett D, Aveyard P.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD006219. doi: 10.1002/14651858.CD006219.pub3. Review.

PMID:
22258966
14.

Mechanisms of change in extended cognitive behavioral treatment for tobacco dependence.

Hendricks PS, Delucchi KL, Hall SM.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):114-9. doi: 10.1016/j.drugalcdep.2009.12.021. Epub 2010 Jan 21.

15.

Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study.

Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, O'Connor K.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):111-8. doi: 10.1016/j.drugalcdep.2011.03.005. Epub 2011 Apr 19.

16.

Predicting smoking cessation. Who will quit with and without the nicotine patch.

Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB.

JAMA. 1994 Feb 23;271(8):589-94.

PMID:
8301790
17.

Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking.

Walker N, Howe C, Bullen C, McRobbie H, Glover M, Parag V, Williman J, Veale R, Nosa V, Barnes J.

BMC Public Health. 2011 Nov 21;11:880. doi: 10.1186/1471-2458-11-880.

18.

The impact of the United Kingdom's national smoking cessation strategy on quit attempts and use of cessation services: findings from the International Tobacco Control Four Country Survey.

Gibson JE, Murray RL, Borland R, Cummings KM, Fong GT, Hammond D, McNeill A.

Nicotine Tob Res. 2010 Oct;12 Suppl:S64-71. doi: 10.1093/ntr/ntq119.

19.

The Smoking Abstinence Questionnaire: measurement of smokers' abstinence-related expectancies.

Hendricks PS, Wood SB, Baker MR, Delucchi KL, Hall SM.

Addiction. 2011 Apr;106(4):716-28. doi: 10.1111/j.1360-0443.2010.03338.x.

20.

Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation.

Weinberger AH, McKee SA, George TP.

Nicotine Tob Res. 2010 Sep;12(9):937-43. doi: 10.1093/ntr/ntq120. Epub 2010 Jul 19.

Items per page

Supplemental Content

Write to the Help Desk